Advertisement
Home »

Consensus Group Identifies 3 Top Tools for Atopic Dermatitis Documentation

Aug 15, 2024

REFERENCES & ADDITIONAL READING

Jacobson ME, et al. Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement. JAMA Dermatol. Published online May 22, 2024. doi:10.1001/jamadermatol.2024.1162

ABOUT THE EXPERTS

  • Professor of Dermatology
    School of Medicine
    Frances J. Storrs, M.D. Medical Dermatology Professor
    Dermatology
    School of Medicine
    Oregon Health & Science University

     

    Eric Simpson, MD, MCR, reported grants from AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Eli Lilly, Kymab, Kyowa Kirin, National Jewish Health, LEO Pharma, Pfizer, Regeneron, Sanofi, Target, and Veriskin, as well as personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics, Bristol Myers Squibb, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, Forte Bio RX, FIDE, Galderma, GlaxoSmithKline, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm, Janssen, Johnson & Johnson, Kyowa Kirin, LEO Pharma, Merck, MJ Holding, Numab Therapeutics AG, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Roivant, Sanofi-Genzyme, Sitryx Therapeutics, Trevi Therapeutics, and Valeant outside the submitted work. Several coauthors reported financial involvement with the pharmaceutical industry.

     

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement